We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer (MELO-D)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01965522
First Posted: October 18, 2013
Last Update Posted: June 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Punam Rana, Juravinski Cancer Center
  Purpose
Investigators plan to carry out a study to investigate two different pills, Vitamin D and melatonin, and whether they can reduce the spread of cancer cells in the tumors of women with breast cancer. These pills are inexpensive and have very few side effects. A large number of studies using cell cultures and animals have shown that both vitamin D and melatonin can help destroy breast cancer cells. However thoughtful and well-designed studies are necessary on humans to see if they can decrease the spread of breast cancer, and possibly even prevent breast cancer. The proposed study aims to understand the anti-cancer activity of vitamin D and melatonin. This knowledge will assist in creating efficient cancer prevention strategies for Canadians. This study will include women with breast cancer who are being planned for surgery, and will assess whether treatment with vitamin D (dose of 2000 IU per day) in a group of 36 women, or melatonin (dose of 20mg per day) in another group of 36 women, or both pills together in yet another group of 36 women, reduces the spread of cancer cells when compared to a fourth group of 36 women who are treated with sugar pills. To do this we will measure a substance in the blood called Ki67, which provides information about the spread of cancer. Investigators will compare the Ki67 levels in the 4 groups, and all women will receive identical appearing pills so they will not know which treatment they received.

Condition Intervention Phase
Early Stage Breast Cancer Drug: Melatonin Drug: Vitamin D Drug: Placebo (melatonin) Drug: Placebo (vitamin D) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer

Resource links provided by NLM:


Further study details as provided by Punam Rana, Juravinski Cancer Center:

Primary Outcome Measures:
  • Ki67 [ Time Frame: From time of initial biopsy to the final surgery, which is on average 4 weeks ]
    The primary outcome is the difference in proliferation rate of Ki67 in the tumour (expressed as the percentage of tumour cells expressing Ki67). Ki67 will be measured on the original core biopsy (pre-treatment) and on the lumpectomy/mastectomy specimen (post-treatment).


Secondary Outcome Measures:
  • microRNA [ Time Frame: At the time of surgery compared to time of biopsy, which is on average 4 weeks ]
    Change in serum profile of microRNA at the time of surgery (lumpectomy or mastectomy, post-treatment) will be compared to the time of initial biopsy (pre-treatment).


Enrollment: 100
Study Start Date: October 2013
Study Completion Date: May 2017
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Melatonin and Vitamin D Drug: Melatonin
Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
Drug: Vitamin D
Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
Experimental: Placebo and Vitamin D Drug: Vitamin D
Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
Drug: Placebo (melatonin)
Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
Experimental: Melatonin and Placebo Drug: Melatonin
Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
Drug: Placebo (vitamin D)
Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
Placebo Comparator: Placebo and Placebo Drug: Placebo (melatonin)
Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
Drug: Placebo (vitamin D)
Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Woman with histologically confirmed invasive breast cancer (ductal, lobular, or mixed)
  • Planned to undergo definitive surgery, either lumpectomy or mastectomy in 3 or more weeks

Exclusion Criteria:

  • Less than 18 years of age
  • Stage IIIB or IV disease
  • Inoperable locally advanced or metastatic breast cancer
  • Neoadjuvant chemotherapy is intended
  • Currently taking vitamin D supplements
  • Currently taking melatonin supplements
  • Previously taking vitamin D or melatonin supplements within the last 3 months
  • Currently taking a multivitamin and not willing to discontinue for the duration of the study
  • Hyperparathyroid disease or other calcium disturbance in the past five years
  • Active renal stones in the last six months
  • Renal failure (creatinine > 190 mmol/L)
  • Hypercalcemia (serum calcium > 2.6 mmol/L)
  • Known pregnancy
  • Participation in another clinical trial where the patient receives any other investigational product
  • Unwilling or unable to provide informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01965522


Locations
Canada, Ontario
St Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 1Y3
Juravinski Cancer Center
Hamilton, Ontario, Canada, L8V 1C3
Sponsors and Collaborators
Juravinski Cancer Center
  More Information

Responsible Party: Punam Rana, Principal Investigator, Juravinski Cancer Center
ClinicalTrials.gov Identifier: NCT01965522     History of Changes
Obsolete Identifiers: NCT02288806
Other Study ID Numbers: MELO-D
First Submitted: October 11, 2013
First Posted: October 18, 2013
Last Update Posted: June 16, 2017
Last Verified: June 2017

Keywords provided by Punam Rana, Juravinski Cancer Center:
Breast cancer
melatonin
vitamin d
ki67

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vitamins
Vitamin D
Ergocalciferols
Melatonin
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Central Nervous System Depressants